Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;77(3):438-443.
doi: 10.1007/s12020-022-03075-y. Epub 2022 May 14.

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen

Antonella Turla  1 , Marta Laganà  1 , Salvatore Grisanti  1 , Andrea Abate  2 , Vittorio Domenico Ferrari  1 , Valentina Cremaschi  1 , Sandra Sigala  2 , Francesca Consoli  1 , Deborah Cosentini  1 , Alfredo Berruti  3
Affiliations
Review

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen

Antonella Turla et al. Endocrine. 2022 Sep.

Abstract

Purpose: The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite toxic, so an adequate supportive therapy is crucial to reduce as much as possible the side effects and maintain the dose intensity of cytotoxic agents.

Methods: We describe the main side effects of the EDP-M scheme and the best way to manage them based on the experience of the Medical Oncology Unit of the Spedali Civili of Brescia. We also deal with the administration of EDP-M in specific frail patients, such as those with huge disease extent and poor performance status (PS) and those with mild renal insufficiency.

Results: In patients with hormone secreting ACC the rapid control of Cushing syndrome using adrenal steroidogenesis inhibitors such as metyrapone or osilodrostat is mandatory before starting EDP-M. Primary prophylaxis of neutropenia with Granulocyte-Colony Stimulating Factors is crucial and should be introduced at the first chemotherapy cycle. Possible mitotane induced hypoadrenalism should be always considered in case of persistent nausea and vomiting and asthenia in the interval between one cycle to another. In case of poor PS. A 24 h continuous infusion schedule of cisplatin could be an initial option in patients with poor PS as well as to reduce the risk of nefrotoxocity in patients with mild renal impairment.

Conclusion: A careful and accurate supportive care is essential to mitigate EDP-M side effects as much as possible and avoid that, due to toxicity, patients have to reduce doses and or postpone cytotoxic treatment with a negative impact on efficacy of this chemotherapy regimen.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patients with poor performance status before A and after (B) chemotherapy (3 cycles) preceded by a single administration of cisplatin (45 mg/m2) in a 24-hour continuous infusion
See this image and copyright information in PMC

Comment in

References

    1. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1–G46. doi: 10.1530/EJE-18-0608. - DOI - PubMed
    1. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A. ESMO Guidelines Committee: Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476–1490. doi: 10.1016/j.annonc.2020.08.2099. - DOI - PubMed
    1. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr Relat Cancer. 2005;12(3):657–666. doi: 10.1677/erc.1.01025. - DOI - PubMed
    1. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–2197. doi: 10.1056/NEJMoa1200966. - DOI - PubMed
    1. Cosentini D, Badalamenti G, Grisanti S, Basile V, Rapa I, Cerri S, Spallanzani A, Perotti P, Musso E, Laganà M, Ferrari VD, Luppi G, Dalla Volta A, Incorvaia L, Sigala S, Russo A, Volante M, Terzolo M, Berruti A. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019;181(6):681–689. doi: 10.1530/EJE-19-0570. - DOI - PubMed

MeSH terms

LinkOut - more resources